NovoCure's Q1 beat, Optune Lua momentum, and global expansion signal strong growth ahead. Find out why NVCR stock is a buy.

The period in brief - financial summary for the first quarter 2025Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 11,1 million (SEK 11,4 million).Operating loss for th ...